Lebrest 2.5mg tablets

Ferron Par Pharmaceuticals

Composition

Letrozole2.5 mg

Each Pack Contains

3 blisters of 10 tablets

Dosage Form

tablet

Dosage formTablet; coated

Flavor

None

W.H.O. Classification

L02B

Available In

Indonesia

Warning

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

NOT RECOMMENDEDThis item should not be used while operating heavy machinery.

Pregnancy

NOT RECOMMENDEDThis item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Indication

Adjuvant treatment
Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer
Extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.
Treatment in postmenopausal women with hormone-dependent advanced breast cancer
Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antiestrogens. Preoperative therapy in postmenopausal women with localized hormone receptor positive breast cancer, to allow subsequent breast-conserving surgery in women not originally considered candidates for this type of surgery. Subsequent treatment after surgery should be in accordance with standard of care.

Dosage

18 YEARS OLD AND ABOVE
The recommended dose of letrozole is 2.5 mg once daily.

— In the adjuvant and extended adjuvant setting, treatment with letrozole should continue for 3 years or until tumor relapse occurs, whichever comes first.

— In patients with metastatic disease, treatment with letrozole should continue until tumor progression is evident.

Food does not affect the absorption of letrozole and the drug may be
administered without regard to meals.

ELDERLY PATIENTS
No dose adjustment is required for elderly patients.

PATIENTS WITH HEPATIC IMPAIRMENT
No dosage adjustment is required for patients with mild to moderate hepatic impairment.

PATIENTS WITH RENAL IMPAIRMENT
No dosage adjustment is required for patients with mild to moderate renal impairment (creatinine clearance ≥10 ml/minute).